IP Library › Granted Patent US 12,416,637
Granted Patent B2
US 12,416,637 · App. 17/624,295 · Granted Sep 16, 2025

Biomarkers for irritable bowel syndrome

Inventors: Kevin Whelan (London, GB); Bridgette Wilson (London, GB); Megan Rossi (London, GB); Chris Probert (Liverpool, GB); Rachael Slater (Liverpool, GB)
G01N33/64G01N2800/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,637
App. No.
17/624,295
Granted
Sep 16, 2025
Kind
B2
Abstract

The present invention relates to a method of determining the probability that an individual has irritable bowel syndrome and whether the individual will respond to dietary intervention. The present invention also provides a method of determining the probability that an individual with irritable bowel syndrome will respond to dietary intervention. There is also provided the use of a compound as defined herein as a biomarker.

Claims (26)

1. A method of determining the probability that an individual has irritable bowel syndrome and whether the individual will respond to dietary intervention, the method comprising the steps of:

i) analysing a stool sample collected from said individual to determine whether a cyclohexane carboxylic acid compound is present; and

ii) if a cyclohexane carboxylic acid compound is present in step i), determining the amount of the cyclohexane carboxylic acid compound that is present and comparing the amount detected with a control value;

wherein the presence of an increased amount of the cyclohexane carboxylic acid compound compared to the control value is indicative of an increased probability that the individual has irritable bowel syndrome and of the probability that the individual will respond to dietary intervention; and wherein the cyclohexane carboxylic acid compound is one or more of a cyclohexane carboxylic acid and/or a cyclohexane carboxylic acid ester.

2. The method according to claim 1 , wherein the cyclohexane carboxylic acid compound is cyclohexane carboxylic acid and/or a cyclohexane carboxylic acid (1-4C) alkyl ester.

3. The method according to claim 1 , wherein the cyclohexane carboxylic acid compound is selected from cyclohexane carboxylic acid methyl ester, cyclohexane carboxylic acid ethyl ester, cyclohexane carboxylic acid propyl ester, and cyclohexane carboxylic acid butyl ester.

4. The method according to claim 3 , wherein the cyclohexane carboxylic acid compound is selected from cyclohexane carboxylic acid ethyl ester, cyclohexane carboxylic acid propyl ester and cyclohexane carboxylic acid butyl ester.

5. The method according to claim 1 , wherein the step of analysing the stool sample involves detecting whether two or more cyclohexane carboxylic acid compound are present.

6. The method according to claim 1 , wherein the presence and amount of the cyclohexane carboxylic acid compound is determined by detecting volatile organic compounds emanating from the stool sample using gas chromatography mass spectrometry (GC-MS).

7. The method according to claim 1 , wherein the individual has one or more symptoms associated with irritable bowel syndrome.

8. The method according to claim 7 , wherein the one or more symptoms associated with irritable bowel syndrome are selected from, diarrhoea, constipation, abdominal cramps and abdominal pain.

9. The method according to claim 1 , wherein the dietary intervention is a low wheat diet.

10. The method according to claim 1 , wherein the dietary intervention is a low FODMAP diet.

11. A method of determining the probability that an individual with irritable bowel syndrome will respond to dietary intervention, the method comprising the steps of:

i) analysing a stool sample collected from said individual to determine whether a cyclohexane carboxylic acid compound is present; and

ii) if a cyclohexane carboxylic acid compound is present in step i), determining the amount of the cyclohexane carboxylic acid compound that is present and comparing the amount detected with a control value;

wherein the presence of an increased amount of the cyclohexane carboxylic acid compound compared to the control value is indicative of an increased probability that the individual will respond to dietary intervention; and wherein the cyclohexane carboxylic acid compound is one or more of a cyclohexane carboxylic acid and/or a cyclohexane carboxylic acid ester.

12. The method according to claim 11 , wherein the cyclohexane carboxylic acid compound is cyclohexane carboxylic acid and/or a cyclohexane carboxylic acid (1-4C) alkyl ester.

13. The method according to claim 11 , wherein the cyclohexane carboxylic acid compound is selected from cyclohexane carboxylic acid methyl ester, cyclohexane carboxylic acid ethyl ester, cyclohexane carboxylic acid propyl ester, and cyclohexane carboxylic acid butyl ester.

14. The method according to claim 13 , wherein the cyclohexane carboxylic acid compound is selected from cyclohexane carboxylic acid ethyl ester, cyclohexane carboxylic acid propyl ester and cyclohexane carboxylic acid butyl ester.

15. The method according to claim 11 , wherein the step of analysing the stool sample involves detecting whether two or more cyclohexane carboxylic acid compound are present.

16. The method according to claim 11 , wherein the presence and amount of the cyclohexane carboxylic acid compound is determined by detecting volatile organic compounds emanating from the stool sample using gas chromatography mass spectrometry (GC-MS).

17. The method according to claim 11 , wherein the individual has one or more symptoms associated with irritable bowel syndrome.

18. The method according to claim 17 , wherein the one or more symptoms associated with irritable bowel syndrome are selected from, diarrhoea, constipation, abdominal cramps and abdominal pain.

19. The method according to claim 11 , wherein the dietary intervention is a low wheat diet.

20. The method according to claim 1 , wherein the dietary intervention is a low FODMAP diet.

Priority Claims (1)
GB 1909709 · Jul 5, 2019 · national
Continuity (1)
Related Publication 20220357333A1 · Nov 10, 2022
References Cited (22)
US 7306953B2 · Probert et al. · 2007 [cited by applicant]
US 20120309048A1 · Ratcliffe et al. · 2012 [cited by applicant]
US 20180038839A1 · Probert et al. · 2018 [cited by applicant]
WO 2004008953 · 2004 [cited by applicant]
WO 2012127213 · 2012 [cited by applicant]
United Kingdom Search Report prepared for United Kingdom Patent Application No. 1909709.6, completed Dec. 10, 2019. [cited by applicant]
PCT Search Report and Written Opinion prepared for PCT Application No. PCT/GB2020/051604, completed Sep. 15, 2020. [cited by applicant]
Ahmed, et al., “An Investigation of Fecal Volatile Organic Metabolites in Irritable Bowel Syndrome,” Mar. 1, 2013, Public Library of Science, vol. 8, Nr: 3, pp. 1-13. [cited by applicant]
Rossi, et al., “Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome.” 2018, Clinical Gastroenterology and Hepatology, No. 16, pp. 385-391. [cited by applicant]
Aras Aradnam, R.P. et al., “Differentiating Coeliac Disease from Irritable Bowel Syndrome by Urinary Volatile Organic Compound Analysis—A Pilot Study,” PLOSone, 2014, 9(10) pp. 1-9. [cited by applicant]
Baranska, A. et al., “Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach,” Alimentary Pharmacology and Therapeutics, 2016, vol. 44, pp. 45-56. [cited by applicant]
Bosch, S. et al., “Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study,” Inflamm Bowel Dis. 2018, 24(11) pp. 2468-2475. [cited by applicant]
Buijck, M. et al., “Sniffing Out Paediatric Gastronintestinal Diseases: The Potential of Volatile Organic Compounds as Biomarkers for Disease,” JPGN, 2016, 63(6) pp. 585-591. [cited by applicant]
Camilleri, M. et al., “Validating Biomarkers of Treatable Mechanisms in Irritable Bowel Syndrome,” Neurogastroenterol Motil., 2014, 26(12) pp. 1677-1685. [cited by applicant]
Hicks, L.C. et al., “Analysis of Exhaled Breath Volatile Organic Compounds in Inflammatory Bowel Disease: A Pilot Study,” Journal of Crohn's and Colitis, 2015, 731-37. [cited by applicant]
Kim, J.H.K., “Biomarkers of Irritable Bowel Syndrome,” J. Neurogastroenterol Mostil., 2017, 23(1) pp. 20-26. [cited by applicant]
Li, X-G. et al., “Fecal calprotectin in differential diagnosis of irritable bowel syndrome,” Journal of Peking University (Health Sciences), 2006, 38(3) pp. 310-313 (abstract only). [cited by applicant]
Mujagic, Z. et al., “A novel biomarker panel for irritable bowel syndrome and the application in the general population,” Scientific Reports, 2016, 6(26420) pp. 1-10. [cited by applicant]
Probert, C. et al., “Volatile Organic Compounds as Diagnostic Biomarkers in Gastrointestinal and Liver Diseases,” J. Gastrointestin Liver Dis., 2009, 18(3) pp. 337-343. [cited by applicant]
Reade, S. et al., “Potential role of fecal volatile organic compounds as biomarkers of chemically induced intestinal Inflammation in mice,” The FASEB Journal, 2019 vol. 33, pp. 1-9. [cited by applicant]
Rossi. M. et al., “Volatile Organic Compounds Predict Response to Both Low Fodmap Diet and Probiotics in Irritable Bowel Syndrome: a Randomised Controlled Trial,” AGA Abstracts, Mol. 1547, pp. S-713 to S-714. [cited by applicant]
Sood, R. and Ford, A.C., “Editorial: volatile organic compounds in irritable bowel syndrome—technology for an accurate and reliable point-of-care test?” Aliment Pharmacol Ther., 2017, vol. 45, pp. 563-564. [cited by applicant]